September 17, 2019
September 17, 2019 – The U.S. FDA has approved a new indication for Erleada® (apalutamide), manufactured by Janssen Pharmaceuticals. The product is now indicated to treat metastatic castration-sensitive prostate cancer (mCSPC).
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global healthcare
July 26, 2019
July 26, 2019 – The U.S. FDA has issued a safety communication cautioning that Xeljanz® (tofacitinib) and
Xeljanz XR® (tofacitinib), manufactured by Pfizer, may increase the risk of blood clots and death when taken at higher doses.
July 25, 2019
July 25, 2019 – The U.S. FDA has approved AccruferTM (ferric maltol), manufactured by Shield Therapeutics, to treat iron deficiency in adults. The product is a new means of treating iron deficiency compared